Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corp Issues FY 2017 EPS Guidance; Revenue Guidance Above Analysts' Estimates-Conference Call


Tuesday, 26 Feb 2013 03:00pm EST 

Celgene Corp announced that for fiscal 2017, it expects roughly $12 billion in top-line revenue and $13 to $14 a share of EPS. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $11.5 billion and EPS of $13.2 for fiscal 2017. 

Latest Key Developments in Pharmaceuticals

Company Quote

89.19
1.36 +1.55%
11 Jul 2014